Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
There is evidence on the beneficial effects of the administration of angiotensin II type 1
(AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models
of liver fibrosis in rodents and limited information in chronic hepatitis C with mild
fibrosis.
The purpose of this study is to investigate the effect of long-term administration of oral
Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic
hepatitis C and fibrosis F2-F3 (METAVIR score).